BRPI0907237A2 - Anticorpo anti-cldn6 - Google Patents

Anticorpo anti-cldn6

Info

Publication number: BRPI0907237A2
Authority: BR; Brazil
Prior art keywords: cldn6 antibody; cldn6; antibody
Prior art date: 2008-01-11

Application number

BRPI0907237-3A

Other languages

English (en)

Inventor

Hiroyuki Aburatani

Shuichi Tsutsumi

Kunihiro Nishimura

Hirofumi Sakumoto

Shigeto Kawai

Original Assignee

Univ Tokyo

Forerunner Pharma Res Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-11

Filing date

2009-01-09

Publication date

2015-07-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40853092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0907237(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-01-09 Application filed by Univ Tokyo, Forerunner Pharma Res Co Ltd filed Critical Univ Tokyo

2015-07-14 Publication of BRPI0907237A2 publication Critical patent/BRPI0907237A2/pt

Classifications

- G01N33/5758—
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- G01N33/5759—
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Oncology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Hospice & Palliative Care (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0907237-3A 2008-01-11 2009-01-09 Anticorpo anti-cldn6 BRPI0907237A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2008004423		2008-01-11
PCT/JP2009/000082 WO2009087978A1 (ja)	2008-01-11	2009-01-09	抗cldn6抗体

Publications (1)

Publication Number	Publication Date
BRPI0907237A2 true BRPI0907237A2 (pt)	2015-07-14

Family

ID=40853092

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0907237-3A BRPI0907237A2 (pt)	2008-01-11	2009-01-09	Anticorpo anti-cldn6

Country Status (12)

Country	Link
US (1)	US9274119B2 (pt)
EP (3)	EP4282428A3 (pt)
JP (1)	JP5848863B2 (pt)
KR (1)	KR20100116179A (pt)
CN (1)	CN101918450A (pt)
AU (1)	AU2009203464A1 (pt)
BR (1)	BRPI0907237A2 (pt)
CA (1)	CA2711557A1 (pt)
MX (1)	MX2010007500A (pt)
RU (1)	RU2010133547A (pt)
SG (1)	SG187457A1 (pt)
WO (1)	WO2009087978A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9809815B2 (en) *	2009-02-20	2017-11-07	Ganymed Pharmaceuticals Ag	Methods and compositions for diagnosis and treatment of cancer
EP2494361B2 (en)	2009-10-26	2019-01-09	Externautics S.p.A.	Ovary tumor markers and methods of use thereof
US8921058B2 (en)	2009-10-26	2014-12-30	Externautics Spa	Prostate tumor markers and methods of use thereof
EP2322555A1 (en)	2009-11-11	2011-05-18	Ganymed Pharmaceuticals AG	Antibodies specific for claudin 6 (CLDN6)
DK2499161T3 (da) *	2009-11-11	2017-11-27	Ganymed Pharmaceuticals Gmbh	Antistoffer, der er specifikke for claudin 6 (cldn6)
MY197016A (en)	2010-02-24	2023-05-20	Immunogen Inc	Folate receptor 1 antibodies and immunoconjugates and uses thereof
AU2011262758B8 (en) *	2010-06-11	2014-09-04	Kyowa Kirin Co., Ltd.	Anti-tim-3 antibody
EP2404936A1 (en)	2010-07-06	2012-01-11	Ganymed Pharmaceuticals AG	Cancer therapy using CLDN6 target-directed antibodies in vivo
FI3434767T3 (fi)	2010-11-30	2026-02-12	Chugai Seiyaku Kk	Sytotoksisuutta aiheuttava terapeuttinen aine
PT2694106T (pt)	2011-04-01	2018-03-05	Immunogen Inc	Métodos para aumentar eficácia de terapia de cancro de folr1
HUE041781T2 (hu) *	2011-05-13	2019-05-28	Ganymed Pharmaceuticals Gmbh	Ellenanyagok klaudin-6-ot expresszáló rák kezelésére
CN107011440B (zh) *	2011-05-13	2021-03-05	加尼梅德药物公司	用于治疗表达密蛋白6之癌症的抗体
AU2012298877B2 (en)	2011-08-22	2018-01-04	Emergent Biosolutions Canada Inc.	Clostridium difficile antibodies
EA031069B1 (ru) *	2012-02-17	2018-11-30	Сиэтл Дженетикс, Инк.	АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αVβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
WO2013143555A1 (en) *	2012-03-26	2013-10-03	Biontech Ag	Rna formulation for immunotherapy
SG10201804260QA (en)	2012-08-31	2018-07-30	Immunogen Inc	Diagnostic assays and kits for detection of folate receptor 1
WO2014132647A1 (ja) *	2013-03-01	2014-09-04	公益財団法人ヒューマンサイエンス振興財団	抗体、フラグメント、医薬組成物、分子及び腫瘍マーカー
WO2015014376A1 (en) *	2013-07-31	2015-02-05	Biontech Ag	Diagnosis and therapy of cancer involving cancer stem cells
JP2016536330A (ja)	2013-08-30	2016-11-24	イミュノジェン，インコーポレイテッド	葉酸受容体１の検出用の抗体及びアッセイ
US10053511B2 (en) *	2013-11-06	2018-08-21	Abbvie Stemcentrx Llc	Anti-claudin antibodies and methods of use
CN113307873B (zh)	2013-11-11	2025-02-18	中外制药株式会社	含有改变了抗体可变区的抗原结合分子
PT3708579T (pt) *	2014-04-01	2024-07-17	Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh	Imunorrecetores e epitopos de células t específicos para claudina-6
MA40921A (fr) *	2014-11-05	2017-09-12	Abbvie Stemcentrx Llc	Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
TWI831044B (zh)	2014-11-11	2024-02-01	日商中外製藥股份有限公司	抗原結合分子、包含抗原結合分子的醫藥組合物以及製造及選擇抗原結合分子之方法
CN106146666B (zh) *	2015-03-26	2019-09-06	科济生物医药（上海）有限公司	靶向cldn6的免疫效应细胞及其制备方法和应用
WO2017049149A1 (en)	2015-09-17	2017-03-23	Immunogen, Inc.	Therapeutic combinations comprising anti-folr1 immunoconjugates
US11479601B2 (en)	2016-06-29	2022-10-25	The Regents Of The University Of California	Antibodies specific to Sonic Hedgehog and method of use thereof
WO2018123949A1 (ja) *	2016-12-28	2018-07-05	国立医薬品食品衛生研究所長が代表する日本国	抗クローディン－２モノクローナル抗体
WO2019048040A1 (en) *	2017-09-06	2019-03-14	Ganymed Pharmaceuticals Gmbh	ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
HUE067603T2 (hu) *	2017-09-18	2024-10-28	Univ California	Klaudin-6 antitestek és rákkezelési eljárások
TWI820044B (zh)	2017-09-29	2023-11-01	日商第一三共股份有限公司	抗體－吡咯并苯二氮呯衍生物複合體
US11952422B2 (en)	2017-12-05	2024-04-09	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
EP3735463A4 (en) *	2018-01-05	2022-03-02	Chugai Seiyaku Kabushiki Kaisha	Cytotoxicity-inducing therapeutic agent
WO2020168059A1 (en)	2019-02-15	2020-08-20	Integral Molecular, Inc.	Claudin 6 antibodies and uses thereof
CA3134055A1 (en)	2019-03-20	2020-09-24	The Regents Of The University Of California	Claudin-6 antibodies and drug conjugates
EP3950061A4 (en)	2019-03-25	2022-11-16	Daiichi Sankyo Company, Limited	ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
MX2022000111A (es) *	2019-07-10	2022-02-10	Chugai Pharmaceutical Co Ltd	Moleculas de union a claudina-6 y usos de las mismas.
MX2022006132A (es)	2019-12-05	2022-06-17	Seagen Inc	Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco.
PH12022552323A1 (en)	2020-03-31	2023-12-04	Chugai Pharmaceutical Co Ltd	Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
WO2022096700A1 (en)	2020-11-06	2022-05-12	Amgen Research (Munich) Gmbh	Polypeptide constructs selectively binding to cldn6 and cd3
CN116940377A (zh) *	2021-03-05	2023-10-24	上海吉倍生物技术有限公司	抗cldn6抗体及其用途
JP2024511319A (ja)	2021-03-09	2024-03-13	ゼンコアインコーポレイテッド	Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
WO2023053282A1 (ja)	2021-09-29	2023-04-06	中外製薬株式会社	がんの治療に用いるための細胞傷害誘導治療剤
KR20250046264A (ko) *	2022-07-29	2025-04-02	레전드 바이오테크 아일랜드 리미티드	클라우딘6 겹합 모이어티 및 이의 용도
JP2025527491A (ja) *	2022-08-15	2025-08-22	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	Ｃｌｄｎ４に対する抗体及びその使用方法
EP4566633A1 (en)	2022-10-31	2025-06-11	Astellas Pharma, Inc.	Antibody-drug complex containing toll-like receptor 7/8 dual agonist compound
IL319951A (en)	2022-11-30	2025-05-01	Integral Molecular Inc	Antibodies targeting claudin 6, including its bispecific formats
WO2024235175A1 (zh) *	2023-05-12	2024-11-21	智泽童康(广州)生物科技有限公司	抗cldn6抗体及其用途
WO2024243561A1 (en)	2023-05-25	2024-11-28	The Regents Of The University Of California	Methods of treating cancer
WO2025162270A1 (zh) *	2024-02-01	2025-08-07	江苏恒瑞医药股份有限公司	抗cldn6抗体、其抗体-药物偶联物及其医药用途
CN118812714B (zh) *	2024-08-21	2025-05-27	广州百吉生物制药有限公司	一种紧密连接蛋白抗体b3及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS58201994A (ja)	1982-05-21	1983-11-25	Hideaki Hagiwara	抗原特異的ヒト免疫グロブリンの生産方法
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
EP0585287B1 (en)	1990-07-10	1999-10-13	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
DE69127627T2 (de)	1990-08-29	1998-02-19	Genpharm Int	Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
CA2119930C (en)	1991-09-23	2002-10-01	Hendricus R. J. M. Hoogenboom	Production of chimeric antibodies - a combinatorial approach
WO1993011161A1 (en)	1991-11-25	1993-06-10	Enzon, Inc.	Multivalent antigen-binding proteins
ES2341666T3 (es)	1991-12-02	2010-06-24	Medimmune Limited	Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
CA2124967C (en)	1991-12-17	2008-04-08	Nils Lonberg	Transgenic non-human animals capable of producing heterologous antibodies
CA2131151A1 (en)	1992-03-24	1994-09-30	Kevin S. Johnson	Methods for producing members of specific binding pairs
EP0652950B1 (en)	1992-07-24	2007-12-19	Amgen Fremont Inc.	Generation of xenogeneic antibodies
US5648267A (en)	1992-11-13	1997-07-15	Idec Pharmaceuticals Corporation	Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
EP0754225A4 (en)	1993-04-26	2001-01-31	Genpharm Int	HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
GB9313509D0 (en)	1993-06-30	1993-08-11	Medical Res Council	Chemisynthetic libraries
JPH09506508A (ja)	1993-12-03	1997-06-30	メディカルリサーチカウンシル	組換え結合タンパク質およびペプチド
HU221385B1 (en)	1994-07-13	2002-09-28	Chugai Pharmaceutical Co Ltd	Reconstituted human antibody against human interleukin-8
DK2180007T4 (da)	1998-04-20	2017-11-27	Roche Glycart Ag	Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US6830894B1 (en) *	1998-11-03	2004-12-14	Adherex Technologies, Inc.	Compounds and methods for modulating claudin-mediated functions
DK1176195T3 (da)	1999-04-09	2013-06-24	Kyowa Hakko Kirin Co Ltd	Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
EA013224B1 (ru)	2000-10-06	2010-04-30	Киова Хакко Кирин Ко., Лтд.	Клетки, продуцирующие композиции антител
AU2002307037B2 (en)	2001-04-02	2008-08-07	Biogen Idec Inc.	Recombinant antibodies coexpressed with GnTIII
US20030228319A1 (en)	2002-04-16	2003-12-11	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
CA2463879C (en)	2001-10-25	2012-12-04	Genentech, Inc.	Glycoprotein compositions
US20040132101A1 (en) *	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
CA2379661A1 (en)	2002-03-28	2003-09-28	Kursad Turksen	Paracellular drug delivery system
WO2003104453A1 (ja)	2002-06-05	2003-12-18	中外製薬株式会社	抗体作製方法
AU2003244817B2 (en) *	2002-06-28	2010-08-26	Domantis Limited	Antigen-binding immunoglobulin single variable domains and dual-specific constructs
AU2003249014B2 (en) *	2002-07-09	2009-07-02	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
ATE541857T1 (de)	2002-09-27	2012-02-15	Xencor Inc	Optimierte fc-varianten und herstellungsverfahren dafür
US20090061485A1 (en)	2004-12-22	2009-03-05	Chugai Seiyaku Kabushiki Kaisha	Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
JP2007020155A (ja)	2005-06-08	2007-01-25	Canon Inc	画像処理装置、画像処理方法、プログラム、及び記憶媒体
CA2624189A1 (en) *	2005-10-03	2007-04-12	Xencor, Inc.	Fc variants with optimized fc receptor binding properties
JP5060068B2 (ja)	2006-06-23	2012-10-31	一般財団法人ファインセラミックスセンター	固体酸化物形燃料電池及びその製造方法

2009
- 2009-01-09 US US12/735,359 patent/US9274119B2/en active Active
- 2009-01-09 EP EP23193707.9A patent/EP4282428A3/en active Pending
- 2009-01-09 WO PCT/JP2009/000082 patent/WO2009087978A1/ja not_active Ceased
- 2009-01-09 RU RU2010133547/10A patent/RU2010133547A/ru not_active Application Discontinuation
- 2009-01-09 EP EP09700588.8A patent/EP2241578B1/en not_active Revoked
- 2009-01-09 CN CN2009801019661A patent/CN101918450A/zh active Pending
- 2009-01-09 BR BRPI0907237-3A patent/BRPI0907237A2/pt not_active IP Right Cessation
- 2009-01-09 CA CA2711557A patent/CA2711557A1/en not_active Abandoned
- 2009-01-09 EP EP16165434.8A patent/EP3064512B1/en active Active
- 2009-01-09 AU AU2009203464A patent/AU2009203464A1/en not_active Abandoned
- 2009-01-09 KR KR1020107017001A patent/KR20100116179A/ko not_active Withdrawn
- 2009-01-09 JP JP2009548907A patent/JP5848863B2/ja active Active
- 2009-01-09 MX MX2010007500A patent/MX2010007500A/es active IP Right Grant
- 2009-01-09 SG SG2013002365A patent/SG187457A1/en unknown

Also Published As

Publication number	Publication date
EP3064512A2 (en)	2016-09-07
JPWO2009087978A1 (ja)	2011-05-26
CN101918450A (zh)	2010-12-15
US20110059469A1 (en)	2011-03-10
EP2241578B1 (en)	2016-04-20
CA2711557A1 (en)	2009-07-16
AU2009203464A1 (en)	2009-07-16
EP3064512A3 (en)	2016-10-19
WO2009087978A1 (ja)	2009-07-16
EP2241578A4 (en)	2012-09-12
RU2010133547A (ru)	2012-02-20
SG187457A1 (en)	2013-02-28
MX2010007500A (es)	2010-10-20
US9274119B2 (en)	2016-03-01
EP2241578A1 (en)	2010-10-20
EP3064512B1 (en)	2023-08-30
EP3064512C0 (en)	2023-08-30
KR20100116179A (ko)	2010-10-29
JP5848863B2 (ja)	2016-01-27
EP4282428A3 (en)	2024-03-20
EP4282428A2 (en)	2023-11-29

Publication	Publication Date	Title
CY2019004I1 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
HRP20171011T1 (hr)	2017-09-22	ANTI-eMET ANTITIJELO
IL212175B (en)	2019-08-29	Muc1* antibodies
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
EP2337798A4 (en)	2012-10-24	SPECIFIC ANTIBODIES OF THE ASB
DK3072906T3 (da)	2021-12-13	Antistofformulering
EP2358392A4 (en)	2012-08-29	ANTIBODY FORMULATION
PT2406284T (pt)	2016-09-29	Anticorpos anti-bcma
PT2813570T (pt)	2018-02-12	Resumo
DE602009000234D1 (de)	2010-11-11	msignals
BRPI0907376A2 (pt)	2015-07-14	Fotobiorretador
PT3045471T (pt)	2017-06-14	Resumo
BRPI0914649A2 (pt)	2015-07-07	Piprazolo-quinazolinas
DE602008003972D1 (de)	2011-01-27	Sitzrücklehnungsmechanismus
DE602008003521D1 (de)	2010-12-30	Sitzrücklehnungsmechanismus
BRPI0909633A2 (pt)	2015-09-22	anticorpos anti-tyrp1
BRPI0817427A2 (pt)	2015-06-16	Anticorpo anti-bst2
DK2271613T3 (da)	2014-07-14	Hydroxymethylcyklohexylaminer
DE602008003970D1 (de)	2011-01-27	Strahlstromkalibriersystem
BRPI0907522A2 (pt)	2019-09-24	biarlamidas
DE112009000183A5 (de)	2011-02-03	Sicherheitsvorreiber
BRPI0909634A2 (pt)	2015-09-22	2-aminoquinolinas
DE602009000862D1 (de)	2011-04-28	Gehwagenbremse
BRPI0912769A2 (pt)	2015-10-13	anticorpos anti-pirb

Legal Events

Date	Code	Title	Description
2015-08-25	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 6A ANUIDADE.
2016-05-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.